Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1 by unknown
Signaling by Lymphocyte Function-associated Antigen 
1 (LFA-1) in B  Cells:  Enhanced Antigen Presentation 
after  Stimulation through LFA-1 
By Vincent T. Moy and Adrienne A. Brian 
From the De~rtment of Chemistry and Cancer Center, Universit2/ of California at San Diegg 
La Jolla,  California 92093 
Summary 
To examine the role of lymphocyte function-associated antigen 1 (LFA-1) expression on murine 
B cells as it pertains to their function in T call activation, we carried out antigen-presentation 
assays in tissue culture wells coated with a purified,  secreted form of the murine intercellular 
adhesion molecule 1 (ICAM-1). We observed a significant decrease  in the concentration of antigen 
required to activate a T cell hybridoma and primary T cells in wells coated with ICAM-1. This 
effect was dependent on the amount of ICAM-1 used to coat the wells and was also observed 
in wells coated with anti-LFA-l-monoclonal antibodies and was blocked by soluble anti-LFA-1 
antibodies. The effect on antigen dose was most pronounced in assays carried out with an ICAM- 
1-deficient mutant B lymphoma cell line, small resting primary B cells, and unfractionated primary 
B cells at low concentrations.  No decrease in the antigen dose was observed if the B ceils were 
chemically fixed or treated with ridn, or when antigen was presented by a HeLa cell line transfected 
with  murine dass  II  major histocompatibility complex (MHC)  genes,  indicating that  the 
immobilized ICAM-1  was mediating its effect through B cell LFA-1, and that B cell protein 
synthesis was required.  The enhancing effect was also observed if the B cells were prepulsed 
with antigen, indicating that improved uptake or processing of antigen, or increased class II 
MHC expression were unlikely mechanisms. 
ntigen-specific  recognition  mediated by  the  antigen 
receptor on T cells and peptide antigens associated with 
MHC dass II-encoded molecules (Ia)  1 on accessory cells is 
strongly enhanced by interacting accessory molecules, in- 
cluding lymphocyte function-associated antigen 1 (LFA-1) and 
its counter receptors, intercellular  adhesion molecule 1 (ICAM- 
1) and ICAM-2 (1-4).  The LFA-1/ICAM-1 interaction has 
drawn considerable attention, as it is important for both class 
I- and dass II-restricted immune responses. The LFA-1/ 
ICAM-1 interaction displays dependence on temperature and 
metabolic energy, and is tightly regulated (5). Adhesion to 
ICAM-l-expressing targets by T cells is modulated by liga- 
tion of the TCR through a mechanism that is independent 
of increased expression of LFA-1 or ICAM-1  and does not 
require protein synthesis but apparently involves the activa- 
tion of protein kinase C (6, 7). Conversely, anti-LFA-1 anti- 
bodies appear to modulate T cell responses to immobilized 
anti-TCR antibodies (8, 9). Further evidence that LFA-1 func- 
tions  in  augmenting TCR-mediated activation  has  been 
provided by recent studies showing that purified  ICAM-1 
1  Abbreviations used in this paper: Ia, MHC class II--encoded  molecules; 
ICAM-1, intercellular adhesion molecule 1; LFA-1, lymphocyte function- 
associated  antigen 1; SEB, staphylococcal  enterotoxin B. 
increases T cell proliferation severalfold  when coimmobilized 
with CD3 mAb (10, 11). 
Although LFA-1 is also present on B cells, its roles in B 
cell activation and differentiation are not weU defined. LFA-1 
on both T cells and B calls appears to play an active role in 
antigen presentation.  Antibodies bound to LFA-1 on B cells 
inhibit antigen-dependent conjugate formation to the same 
degree as antibodies bound to LFA-1 on T cells (12). EBV- 
transformed B cells from patients with a congenital deficiency 
in the expression of  LFA-1 are poor allo-stimulators for normal 
PBL, even though ICAM-1 expression is normal in these pa- 
tients (13). Engagement of MHC dass II-encoded molecules 
activates LFA-l-dependent B cell adhesion, providing a mech- 
anism by which T and B cell adhesion may be reciprocally 
activated during antigen presentation (14). LFA-1 may also 
provide signals involved in B ceU activation.  An antibody 
against the oe chain of  LFA-1 has been shown to mimic effects 
on B cells typically associated with IL-4, including increased 
MHC class II expression on resting B ceils (15), and B cells 
derived from LFA-l-deficient  patients  fail to produce Ig in 
the presence of syngeneic or aUogeneic T cells activated by 
PWM (16). 
In the work presented here we examine the role of LFA-1 
in stimulating B call function in the presentation of antigen. 
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increases the efficiency of B cells in antigen presentation as 
measured by a reduction in the antigen dose required for stim- 
ulation of lymphokine production by T cells. In our system, 
the LFA-1 molecules involved are spatially distinct from the 
B cell-T cell contact region, suggesting that the enhance- 
ment in APC function is not from a direct effect on adhesion. 
Materials and Methods 
Reagents and Antibodies.  The purified  ICAM-1 used in this work 
is a secreted  recombinant  form (sICAM-1)  described  previously  (11). 
Chicken egg  albumin (OVA, grade V)  and staphylococcal en- 
terotoxin B (SEB) were purchased from Sigma Chemical Co. (St. 
Louis, MO). The peptide, OVA (323-339) was synthesized at a 
campus facility  and HPLC purified. Ricin whole toxin (Ricinus com- 
munis) was purchased from Calbiochem-Behring  Corp. (San  Diego, 
CA).  Supernatants from FD441.8, M17/4.2,  (anti-LFA-1), and 
BE29G1 (anti-ICAM-1)  were used for fluorescence  staining. R-PE- 
labeled goat anti-rat antibody was purchased from Fisher Scientific 
Co. (Pittsburgh, PA). For use in direct staining, the mAb MKD6 
(anti-IA  a) was purified from hybridoma supernatants by protein 
A affinity  chromatography.  Purified  antibody  was hbeled with FITC 
(Molecular Probes Inc., Eugene, O1~) overnight at 4~  in 100 nM 
NaHCO3, pH 8.3, and dialyzed  against three changes of PBS. The 
hybridomas, FD441.8, MKD6, and M17/4.2, were obtained from 
the  American Type Culture  Collection  (Rockviile, MD)  and 
BE29G1 was generated in our laboratory (11). 
CellLines.  3D0-54.8,  a Th cell hybridoma, was obtained from 
Drs. J. Kappler and P. Marrack (National Jewish Hospital and Re- 
search Center, Denver, CO) (17). A20.M1, a B call lymphoma, 
was provided  by Dr. K. Rock (Dana Farber  Cancer Institute, Boston, 
MA) (18). IAd.S2, a HeLa cell line transfected with A~  a and A~  d, 
was a generous gift from Dr. Luc Teyton (Research Institute of 
Scripps Clinic, La Jolla, CA). 3DO-54.8 and A20.M1 were main- 
tained in complete medium consisting of 10% FCS (Gibco Labora- 
tories, Grand Island, NY), 2 mM glutamine (Irvine Scientific,  Santa 
Ana, CA), 10 mM Hepes, 50/zM 2-ME, 100 U/m1 penicillin (Ir- 
vine Scientific),  and 100/~g/ral streptomycin  sulfate  (Irvine  Sdentific) 
in RPMI 1640 (Whittaker Bioproducts, Inc., Walkersville, MD). 
IAd.S2 was maintained in complete medium supplemented with 
400/~g/ml of G418 (Geneticin) (Gibco Laboratories). 
Splenic B ceils were isolated from BALB/c mice (Simonsen 
Laboratories, Inc., Gilroy, CA). Spleens from killed animals were 
removed and teased apart to liberate calls. Erythrocytes were lysed 
by hypo-osmotic shock. The B ceil population was enriched by 
negative sdection with a cocktail of anti-T cell antibodies, followed 
by rabbit complement (Cedarlane Laboratory Ltd., Hornby, On- 
tario, Canada) as described previously (19). Viable cells were iso- 
lated on Ficoil (Lymphocyte  M; Cedarlane Laboratory Ltd.), and 
washed before use. To separate high and low density B cell popula- 
tions, purified  B cells  were centrifuged through a step gradient com- 
posed of 100, 70, 60, and 50% Percoll (Sigma  Chemical  Co.), respec- 
tively, at 2,300 g for 12 min at 5~  (20). High and low density 
B cells were recovered from the 60-70%  and 50% Percoil frac- 
tions, respectively. 
T lymphocytes  were prepared from spleens  of B10.Br mice (The 
Jackson Laboratory,  Bar Harbor, ME). After erythrocytes  were lysed 
by hypo-osmotic shock and adherent cells depleted by a 2-h incu- 
bation in tissue culture dishes at 370C, resting CD4 § cells were 
enriched  by negative  selection  with CD8 mAb (HO-2.2), anti-MHC 
class II mAb (Y-17), mAb J11.d2, anti-TAC  mAb (7D4), followed 
by incubation with rabbit complement. Viable cells were isolated 
on Ficoll and washed before use. 
Antigen Presentation Assays.  Antigen presentation was carried 
out in 96-well tissue  culture plates (Costar, Cambridge, MA). Where 
specified, wells were treated with slCAM-1 in PBS for 3 h at 37~ 
or overnight at 4~  Before assays, unbound protein was removed 
by three washes with PBS. Unless indicated, 5  x  104 each of T 
cells and accessory cells were cultured with the  antigen OVA 
(323-339) in complete medium for 24 h. 50/xl of the culture su- 
pernatant was removed and assayed  for Ib2 using the Ib2-depen- 
dent cell line NK. 104 NK cells were cultured with test superna- 
rant  in  200  /~1  total  vol  for  16  h,  pulsed with  0.5  #Ci 
[3H]thymidine  for 6 h, and harvested. The NK cells were obtained 
from Dr. S. Swain (University of California at San Diego, La  Jolla, 
CA). 
Ricin Treatment  of Cells.  Cells  were cultured in complete  medium 
containing specified  concentrations of ricin for 2 h at 37~  They 
were then washed  three times and resuspended  in complete  medium. 
After a 2-h incubation, cells were washed and used in assays. To 
confirm the inhibition  of protein  synthesis, washed cells were 
resuspended in complete medium minus leucine. After a 2-h incu- 
bation, 1 #Ci of [3H]leucine (New England Nuclear, Boston, MA) 
was added. Cells were harvested after another 4-h incubation and 
percent of protein synthesis was calculated from the ratio of 3H 
incorporated by ricin-treated cells to incorporation by untreated 
control cells. 
Ghtaraldehyde Fixation of Cells.  Ceils  were washed twice with 
PBS and resuspended in 0.05% glutaraldehyde/PBS solution to 5 
x  106 cells/ml. After 30 s at room temperature, the reaction was 
quenched by the addition of an equal volume of 0.2 M lysine in 
PBS. Cells were washed three times with PBS and resuspended in 
complete medium. Fixed cells were used immediately. 
Results and Discussion 
The aim of the current study was to analyze the function 
of LFA-1 in B cells as it pertains to their role in antigen pre- 
sentation to T  cells. In the approach used here,  we carried 
out antigen-presentation  assays in microtiter wells coated with 
a purified,  secreted  form of routine ICAM-1  (slCAM-1). 
Hence, slCAM-1 is provided to B cell LFA-1 on a surface 
separate from the T cell surface, enabling us to distinguish 
functions for LFA-1 other than direct cell-cell adhesion. Most 
of the experiments discussed below used a T cell hybridoma, 
3DO-54.8,  specific for OVA peptide (323-339)  and IA  a and 
a B cell lymphoma, A20.M1, a descendent of the A20 cell 
line, selected after 3/-irradiation  based on its ability to resist 
killing by CTL (18). This defect has been attributed to low 
ICAM-1 expression and is corrected by transfection with the 
ICAM-1 cDNA. Both 3DO-54.8 and A20.M1 are LFA-1 posi- 
tive,  but are low expressers of ICAM-1,  as determined by 
flow cytometry. Therefore, when using these cell lines, the 
presence of ICAM-1 in our assays is controlled by the amount 
of purified slCAM-1 initially introduced onto the assay plates. 
The slCAM-1 used in this study is biologically active in that 
it promotes LFA-l-dependent cell adhesion and augments T 
cell proliferation when coimmobilized with CD3 mAb (11). 
Immobilized ICAM-1  Enhances Antigen  Presentation by B 
Cells.  Fig.  1 A  shows the results of a series of antigen- 
presentation experiments carried out in plates  coated with 
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Figure 1.  (A) Enhancement of antigen presentation by immobilized 
slCAM-1. Specified  amounts of purified slCAM-1 were incubated in assay 
wells before addition of 3DO-54.8 cells and A20.M1 cells, 5  x  104 of 
each. [3H]TdR incorporation by NK cells indicates the level of T cell re- 
sponse. (B) Inhibition  by soluble anti-LFA-1 mAb. Where indicated, assay 
wells were coated with 1/~g of slCAM-1.  FD441.8 concentration was 
40 /~g/ml.  (C)  Enhancement of antigen presentation  by immobilized 
anti-LFA-1 mAb M17/4.2. 
varying amount of slCAM-1. The presence of immobilized 
slCAM-1  led to a marked decrease in the antigen dose re- 
quired to activate IL-2 production by the T cell hybridoma, 
3DO-54.8.  No II.-2 was detected in the absence of antigen 
in either treated or untreated wells. The magnitude of the 
shift in the antigen dose-response  profile depended on the 
amount of slCAM-1  initially  incubated in  the wells. At 
the optimal amounts, 1-5/~g/well, the reduction in the an- 
tigen dose required for half-maximal T cell stimulation was 
10-fold. As shown (Fig. 1 B),  this effect was inhibited by 
the presence of a soluble anti-LFA-1 mAb (FD441.8) and 
reproduced by immobilized anti-LFA-1  mAb (Fig.  1 C), 
demonstrating that the observed  effect  was mediated by LFA-1. 
In experiments carried out with BALB/c splenic B cells (Fig. 
2), we observed a smaller shift in the antigen dose-response 
in the presence of slCAM-L However, the magnitude of the 
effect was greater at lower cell densities and quite pronounced 
at around 2,000 B cells/well. The unfractionated splenic B 
cell population expresses ICAM-1 at various levels (21), and 
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Figure 2.  ICAM-1 enhancement of antigen presentation by splenic B 
cells depends on B cell number. Tissue culture wells were initially  treated 
with 500 ng of ICAM-1 (e) or left untreated (O). Assays were carried 
out with 5  x  104 3DO-54.8 and the indicated number of BALB/c splenic 
B cells. 
at high B cell concentrations  this may have masked the en- 
hancement provided by the immobilized slCAM-1. Similarly, 
the effects of slCAM-1  were less pronounced in antigen- 
presentation assays employing the parent A20 cell line (data 
not shown), but were again evident at lower densities of A20 
cells. Splenic B cells were fractionated into resting, high den- 
sity, and activated, low density populations to determine their 
sensitivity to slCAM-1 during antigen presentation. Resting 
B cells were markedly more responsive to slCAM-1 than ac- 
tivated  B cells (Fig. 3),  and the presence of immobilized 
slCAM-1 resulted in a 5-fold decrease in the stimulatory an- 
tigen dose range. To determine whether a similar effect would 
be observed in antigen presentation  to normal T  cells, we 
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Figure 3.  ICAM-1  enhancement  of antigen presentation by (A) high 
density, resting B cells and (B) low density, activated B cells. Tissue cul- 
ture wells were initially treated with 1 #g of slCAM-1 (O) or left un- 
treated (O). Both assays were carried out with 5  x  104 3DO-54.8 and 
2  x  104 BALB/c splenic B cells. 
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Figure  5.  ICAM-1  does  not  enhance  antigen  presentation  by  (A) 
glutaraldehyde-fixed  A20.M1  cells or (B) IAa-transfected  HeLa cells (com- 
pared to live A20.M1).  Assay wells were initially treated with 500 ng of 
ICAM-1 (e)  or left  untreated (O). 
carried out experiments employing resting B cells and resting 
CD4 + T  lymphocytes from spleen.  The superantigen,  SEB, 
activates  all T  cells bearing Va3 and Va8 antigen receptors, 
but is not MHC restricted  (22). As shown (Fig. 4), the pre- 
sentation of the superantigen by resting B cells to T lympho- 
cytes is greatly enhanced by slCAM-1.  This shows that the 
enhancing effect of slCAM-1 does not depend on the nature 
of the  antigen. 
We previously demonstrated that slCAM-1  augments ac- 
tivation of T  cells stimulated by CD3 mAb.  This enhance- 
ment occurs only when slCAM-1 is coimmobilized with CD3 
mAb and not when slCAM-1  and CD3 mAb are immobi- 
lized on different surfaces (11).  Since slCAM-1  and Ia were 
spatially  distinct in the current experimental system, we sus- 
pected that the slCAM-1  was acting on the B cells and not 
on the T cells.  To investigate this hypothesis, we carried out 
experiments using IAa.S2,  a HeLa cell line transfected  to ex- 
press  I-A  a,  and  glutaraldehyde-fixed  A20.M1  cells as acces- 
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Figure 4.  ICAM-1 enhances the presentation of the superantigen, SEB, 
by resting B cells to resting T lymphocytes.  Tissue culture wells were ini- 
tially treated  with 1/~g of sICAM-1 (0) or left untreated (O). Assays 
were  carried out with  2  x  104  B10.Br  T  lymphocytes  and  5  x  104 
BALB/c splenic B cells. 
sory cells. As shown in Fig. 5, IL-2 production by the T cells 
was the same in sICAM-l-treated and untreated weUs when 
antigen was presented by fixed A20.M1  (A) or IAd.S2  (B), 
demonstrating  that sICAM-1  was not mediating  its effects 
on T ceils directly, but instead was acting through the B cells. 
Enhancement of  APC Function by ICAM-1  Requires  B Cell 
Protein Synthesis.  These results argue that a fimctional antigen- 
presenting cell is essential,  suggesting that this enhancement 
in antigen presentation  might be associated with the upregu- 
lation  or de novo  expression  of a protein.  To determine if 
protein  synthesis  is  required,  A20.M1  was pretreated  with 
ricin, an irreversible protein synthesis inhibitor that catalyti- 
cally inactivates  ribosomes.  2 h after treatment with ricin at 
0.1 ng/ml, protein synthesis in A20.M1 was inhibited by 80% 
as  determined  by  incorporation  of  [3H]leucine  (Fig.  6). 
When pretreated  with ricin at 1 ng/ml,  A20.M1  ceUs were 
still  able  to  process  native  OVA  (Fig.  7  A)  even  though 
[3H]leucine  incorporation was inhibited by 95%.  At concen- 
trations of 10 ng/ml  and above,  these calls  were incapable 
of processing antigen (Fig. 7 A), but were stiU able to present 
peptides to T  calls (Fig.  7,  C and D),  although the dose re- 
sponse was shifted to slightly higher peptide concentrations. 
Figure 6.  Inhibition of protein 
synthesis in ricin-treated  A20.M1 
cells. A20.M1 cells were  treated 
with specified concentrations  of 
ricin as described in Materials  and 
Methods. 
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Figure 7.  ICAM-1 does not enhance antigen presentation by ricin-treated 
A20.M1 cells. A20.M1 cells were treated with specified concentrations 
of ricin as described in Materials and Methods.  (A) The effect of ricin 
on presentation of whole OVA. (B-D) Presentation of OVA peptide by 
untreated and ricin-treated A20.M1 cells in slCAM-l-treated wells (500 
ng/well) (e) and untreated wells (O). 
In the control experiment (Fig. 7 B), approximately five times 
more antigen was needed to activate 3DO-54.8 cells in un- 
coated wells than in wells coated with slCAM-1. When the 
A20.M1 cells were treated with 1 ng/ml ricin, the stimula- 
tory antigen concentration was approximately 50% higher 
in the uncoated wells. The effect of slCAM-1 in enhancing 
antigen presentation  was therefore diminished about 90% 
by treatment of the A20.M1 cells with 1 ng/ml ricin, where 
antigen processing is relatively unaffected. This value is com- 
parable with the inhibition of protein synthesis at this ricin 
concentration.  [3H]Leucine incorporation  in 3DO-54.8 was 
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Figure 8.  ICAM-1  enhances antigen presentation  by antigen-pulsed 
A20.M1 cells. A20.M1 cells were incubated with OVA(323-339) for 2 h 
at 37~  and washed three times before use. Assay wells were treated with 
the amounts of slCAM-1 indicated. 
unaffected by coculture with A20.M1 cells treated with ricin 
at concentrations up to 100 ng/ml (data not shown). Thus, 
we concluded that B cell protein synthesis is required for the 
enhancement of APC function and the enhancement is not 
an effect on antigen processing. 
Enhancement of  APC Function Does Not Result  from Increased 
Expression of MHC Class II, LFA-I, or ICAM-1.  Immuno- 
fluorescence staining  of cells cultured in sICAM-l-coated 
dishes revealed no changes in the expression levels of Ia on 
the B cell population,  or LFA-1 and ICAM-1 on either the 
T  or B cell populations  (data not shown). In these assays, 
106 each of 3DO-54.8 and A20.M1 were cultured with var- 
ious concentrations of OVA on either sICAM-l-treated tissue 
culture dishes or untreated dishes for 14 h. A third of the 
cells from each culture were directly stained with fluorescei- 
nated MKD6 (anti-I-A  d) to monitor changes in MHC-dass 
II expression. Expression of LFA-1 and ICAM-1 was measured 
by using M17/4.2 (anti-LFA-1) and BE29G1 (anti-ICAM- 
1), respectively, followed by PE-labeled goat anti-rat anti- 
bodies. To distinguish  B cells from T  calls, the cells were 
then stained with fluoresceinated MKD6. In parallel, super- 
natants  from the cultures were assayed for the presence of 
II,-2 to verify that the antigen concentrations  used corre- 
sponded to the region in the antigen dose-response  profile 
where the effects of ICAM-1  were evident. 
Concerns over the possibility that an undetectable change 
in MHC class II expression might still result in a significant 
improvement in antigen presentation led us to devise a func- 
tional assay to investigate further the role of Ia in these ex- 
periments. To separate antigen presentation from antigen pro- 
cessing, A20.M1 cells were pulsed with OVA (323-339) for 
2 h at 37~  washed extensively, and introduced to T ceUs 
in either sICAM-l-treated or untreated plates. The results 
from this assay show that T ceils cultured in the slCAM-1- 
treated wells responded at significantly lower antigen con- 
centrations than those cultured in untreated plates (Fig. 8). 
Since the number of Ia-peptide complexes was predetermined 
in this experiment, the observed improvement in the antigen 
dose-response profile was not related to the upregulation of 
MHC dass II expression or the eiticiency with which the 
cells can promote the formation of Ia-peptide complexes, i.e., 
antigen processing. 
It was conceivable that A20.M1 cells were producing lym- 
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from slCAM-1 and T cells, as it has been reported that cross- 
linking of membrane Ig on A20 cells results in the secretion 
of II.-2 (23).  3DO-54.8  cells,  treated with ricin to inhibit 
their own Ib2 production, were cultured with A20.M1 and 
antigen in slCAM-l-coated plates overnight. Supernatants 
collected from these cultures did not stimulate any prolifera- 
tion of the NK cells. These supernatants also failed to en- 
hance T  cell responses when added to subsequent antigen- 
presentation assays, suggesting that the effect of ICAM-1 on 
antigen presentation is not mediated by a secreted protein 
produced by the A20.M1  cells (data not shown). 
Because we could not find evidence for a secreted factor, 
we used several approaches to detect a change in the cell sur- 
face phenotype of A20.M1 cells. A20.M1 cells, harvested after 
being in culture on slCAM-l-coated plates for 12 h, were 
assayed for their ability to augment T cell activation. These 
cells were either glutaraldehyde fixed or used directly in the 
subsequent assays. The slCAM-l-treated cells, either fixed 
or alive, were no better at presenting antigen than the cells 
not exposed to slCAM-1 in the primary culture. These ex- 
periments were extended to include T  cells and antigen in 
the primary culture, as signals  from both ICAM-1 and T 
cells might be necessary. In one set of experiments, the mixed 
cell population was glutaraldehyde fixed. For experiments re- 
quiring functional A20.M1,  the B cells were isolated from 
the mixed cell population by depletion of the T  cells with 
anti-T cell antibodies and complement. Neither the fixed T 
and B cells nor the isolated A20.M1 demonstrated any im- 
provement in antigen presentation in comparison with cells 
that  were initially cultured in  untreated dishes  (data not 
shown). From these experiments, we conclude that slCAM- 
1-induced factors,  if present, must be transiently expressed 
or labile  to chemical fixation. 
Although we have not identified the molecular basis for 
the ICAM-l-mediated enhancement in APC function, our 
data indicate that it is mediated through B cells. To demon- 
strate this, we carried out three different experiments in which 
the T  cell was confronted with a source of MHC class II 
and antigen in the presence of immobilized ICAM-1. In the 
first of these, the B cell was chemically fixed, but still capable 
of presenting peptide antigen. In the second experiment, an- 
tigen was presented by a HeLa cell line transfected with genes 
for IA  a. In the third experiment, the B cell line was treated 
with an irreversible inhibitor of protein synthesis. After this 
treatment the B cell line still presented peptide antigens, as 
in the case of the chemically fixed cells. In all three situations 
the presence of immobilized slCAM-1 was of no consequence 
and had no effect on the antigen dose-response profile. It 
is possible that the presence of ICAM-1 is somehow facilitating 
the interaction of the B and T  cells, but it does not do so 
if the B cell is not alive and active,  or if it is replaced by a 
nonphysiological APC. 
Our results indicate that ligation of LFA-1 provides signals 
in B cells that improve their ability to present antigen to T 
cells. This effect is more pronounced for small B cells than 
for the lower density, more activated, population.  It is an 
active B cell response that requires protein synthesis, but does 
not involve an effect on antigen processing, or increased ex- 
pression of MHC class II, LFA-1, or ICAM-1. Thus, in T-B 
interactions, LFA-1 contributes to T  cell activation in mul- 
tiple ways: by its contribution to cell-cell adhesion which 
increases the effldency of antigen recognition, through signals 
in T  cells that augment activation, and through signals in 
B cells that increase the effidency of antigen presentation. 
In a scheme similar to events in T cells (7), it is conceivable 
that the signals from immobilized ICAM-1 and T cells acti- 
vate B cell LFA-1 to undergo a transition to a high avidity 
state. Similarly, these signals could activate an alternative adhe- 
sion pathway, possibly involving the murine homologue of 
B7/BB1.  Defined as a B cell activation marker in humans, 
B7/BB1 is the ligand for CD28, a receptor that is expressed 
on a majority of T  cells. Ligation of B7/BB1  with CD28 
has been shown to augment T  cell activation (24,  25). 
It  is important  to  note that  the effect of immobilized 
sICAM-1 on B cell function observed in these experiments 
differs in a critical way from effects seen previously on T cells. 
In experiments using purified ICAM-1, we and others have 
observed enhanced T  cell proliferation only when ICAM-1 
is coimmobilized with a TCK ligand.  In the experiments 
described here there was no requirement for coimmobiliza- 
tion of ICAM-1 and ligands for either MHC class II or sur- 
face Ig. In fact, the variation in the magnitude of the effect 
with B cell concentration (see Fig. 2) suggests that B cells 
are able to provide this signal to one another. During lym- 
phocyte recirculation in vivo B cells pass from the circulation 
into the lymphoid organs, where they encounter ICAM-I-ex- 
pressing cells at high density, as well as antigen if it is present. 
LFA-l-mediated signals, delivered by close cell-cell contact, 
could thus increase the ability of B cells to act as APCs in 
an environment where they are most likely to encounter both 
antigen and T  ceils. T  cells also express  ICAM-1,  and the 
interaction of T  cell-ICAM-1 with B ceI1-LFA-1 may not 
only be  important  in  stabilizing  the  cell-cell interaction 
through adhesion, but also in providing signals that enhance 
antigen presentation by as yet undefined mechanisms. 
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